查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生技药品药物研发市场 - 全球与区域分析（2023-2033）
市场调查报告书
商品编码
1389594

生技药品药物研发市场 - 全球与区域分析（2023-2033）

Biologics Drug Discovery Market - A Global and Regional Analysis, 2023-2033
出版日期: | 出版商: BIS Research | 英文 155 Pages | 商品交期: 1-5个工作天内

价格
简介目录

生技药品药物研发代表了药物研究和开发的革命性范例，它利用生物系统固有的复杂性来创建有针对性的治疗性介入。

与传统的小分子药物不同，生物製药是大而复杂的分子，例如蛋白质、抗体和核酸，通常源自活生物体。这种方法可以对疾病做出更精确和量身定制的反应，特别是在慢性病和自体免疫疾病领域。生技药品药物研发的过程包括阐明目标疾病的复杂生物学、识别关键生物分子和途径，以及设计可以调节这些目标的疗法。这种对生物复杂性的细緻入微的理解使得能够开发出比传统药物具有更高特异性和功效的治疗方法，并且通常副作用更少。

该报告考察了全球生技药品药物研发市场，并提供了市场概述，包括按方法、製造类型、地区和参与市场的公司概况分類的趋势。

目录

第一章市场：产业展望

  • 趋势：当前和未来的影响评估
  • 供应链概览
  • 研究发展回顾
  • 监管状况
  • COVID-19 影响分析
  • 市场动态概览

第二章 应用

  • 应用细分
  • 应用概述
  • 全球生物药物研发市场（按方法）
    • 目标识别/检验
    • 命中生成/检验
    • 线索识别
    • 潜在客户优化
  • 全球生物药物研发市场（按製造类型）
    • 内部製造
    • 契约製造

第三章 产品

  • 产品细分
  • 产品概要
  • 全球生技药品药物研发市场（按类型）
    • 单株抗体
    • 重组蛋白
    • 其他的

第四章 区域

  • 区域概况
  • 促进因素和抑制因素
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区

第五章市场-竞争形势与公司概况

  • 竞争形势
  • 公司简介
    • AbbVie, Inc.
    • Amgen, Inc.
    • Astellas Pharma, Inc.
    • AstraZeneca, Plc
    • Bayer AG
    • Bicon Ltd.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Eli Lily and Company
    • F.Hoffmann-La Roche AG
    • GenScript
    • Gilead Sciences, Inc.
    • GlaxoSmithKline, Plc
    • Johnson and Johnson
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk
    • Pfizer
    • Sanofi
    • Teva Pharmaceutical Industries, Ltd.
简介目录
Product Code: BHP0493SB

“Advancements in Biologics Drug Discovery Propel Market Growth.”

Biologics drug discovery represents a revolutionary paradigm in pharmaceutical research and development, leveraging the inherent complexities of biological systems to create targeted therapeutic interventions. Unlike traditional small-molecule drugs, biologics are large, complex molecules typically derived from living organisms, such as proteins, antibodies, or nucleic acids. This approach allows for a more precise and tailored response to diseases, particularly in the realm of chronic conditions and autoimmune disorders. The process of biologics drug discovery involves unraveling the intricate biology of the targeted disease, identifying key biomolecules or pathways, and designing therapeutic agents that can modulate these targets. This nuanced understanding of the biological intricacies enables the development of therapies that exhibit higher specificity, efficacy, and often fewer side effects compared to conventional drugs.

  • The report highlights the transformative impact of biologic therapies on individuals suffering from chronic inflammatory diseases, showcasing how these treatments have not only reduced dependency on health and welfare systems but also improved patients' physical function, enabling them to live more independently.
  • The report delves into various factors influencing the industry, including recent trends, technological advancements, and regulatory aspects. It outlines the market's segmentation based on product, method, manufacture, and geographical regions.
  • The report strategically segments the global biologics drug discovery market based on the phase of discovery, manufacturing type, and product type.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent companies in this market are:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca, Plc
  • Bayer AG
  • Bicon Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lily and Company
  • F.Hoffmann-La Roche AG
  • GenScript
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Plc
  • Johnson and Johnson
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries, Ltd.

Key Questions Answered:

  • What are the major market drivers, challenges, and opportunities in the global biologics drug discovery market and their case studies?
  • How the biologics drug discovery market evolve and what did is its scope in the future?
  • What is the market share of the leading segments and sub-segments of the global biologics drug discovery market in 2023 and 2033?
  • How will each segment of the global biologics drug discovery market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2033?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period between 2023 and 2033?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What will be the growth rate of the outsourced manufacturing segment during the forecast period?

Table of Contents

1. Markets: Industry Outlook

  • 1.1. Trends: Current and Future Impact Assessment
    • 1.1.1. Usage of AI/ML to Accelerate Drug Development
    • 1.1.2. Growing Emphasis on Developing Biosimilars and Biobetters
    • 1.1.3. Shift Towards Targeted and Precision Medicine
  • 1.2. Supply Chain Overview
    • 1.2.1. Value Chain Analysis
  • 1.3. R&D Review
    • 1.3.1. Patent Filing Trend by Country, by Company
  • 1.4. Regulatory Landscape
  • 1.5. Impact Analysis COVID-19
  • 1.6. Market Dynamics Overview
    • 1.6.1. Market Drivers
    • 1.6.2. Market Restraints
    • 1.6.3. Market Opportunities

2. Application

  • 2.1. Application Segmentation
  • 2.2. Application Summary
  • 2.3. Global Biological Drug Discovery Market (by Method)
    • 2.3.1. Target Identification/ validation
    • 2.3.2. Hit Generation/ Validation
    • 2.3.3. Lead Identification
    • 2.3.4. Lead Optimization
  • 2.4. Global Biological Drug Discovery Market (by Manufacture Type)
    • 2.4.1. In-House Manufacturing
    • 2.4.2. Outsourced Manufacturing

3. Product

  • 3.1. Product Segmentation
  • 3.2. Product Summary
  • 3.3. Global Biologics Drug Discovery Market (by Type)
    • 3.3.1. Monoclonal Antibodies
      • 3.3.1.1. Global Monoclonal Antibodies by Method
        • 3.3.1.1.1. Target Identification/ Validation
          • 3.3.1.1.1.1. Functional Genomics/Proteomics
          • 3.3.1.1.1.2. Cell-based Assay
          • 3.3.1.1.1.3. CRISPR/Knockout Studies/Cas9
          • 3.3.1.1.1.4. Animal/Disease Based Models
          • 3.3.1.1.1.5. Computational/in-Silico/Bioinformatics
        • 3.3.1.1.2. Hit Generation/ Validation
          • 3.3.1.1.2.1. mAb Sequencing
          • 3.3.1.1.2.2. Hybridoma Screening
          • 3.3.1.1.2.3. Customized Synthetic Library Screening
          • 3.3.1.1.2.4. Phase Display Screening
          • 3.3.1.1.2.5. High-Throughput Screening
          • 3.3.1.1.2.6. Others
        • 3.3.1.1.3. Lead Identification
          • 3.3.1.1.3.1. Phase Display
          • 3.3.1.1.3.2. ELISA/ADCC & CDC Assay
          • 3.3.1.1.3.3. Array-Based Screening
          • 3.3.1.1.3.4. Hybridoma Screening and Humanization
          • 3.3.1.1.3.5. Bioanalytical Analysis
          • 3.3.1.1.3.6. Others Assays
        • 3.3.1.1.4. Lead Optimization
          • 3.3.1.1.4.1. Humanization
          • 3.3.1.1.4.2. Affinity Analysis
          • 3.3.1.1.4.3. Protein Engineering
          • 3.3.1.1.4.4. In-Vitro/In-Vivo efficacy Assays
          • 3.3.1.1.4.5. Others
    • 3.3.2. Recombinant Proteins
      • 3.3.2.1. Global Protein Recombinant by Method
        • 3.3.2.1.1. Target Identification/ Validation
          • 3.3.2.1.1.1. Functional Genomics/Proteomics
          • 3.3.2.1.1.2. Cell-based Assay
          • 3.3.2.1.1.3. CRISPR/Knockout Studies/Cas9
          • 3.3.2.1.1.4. Animal/Disease Based Models
          • 3.3.2.1.1.5. Computational/in-Silico/Bioinformatics
        • 3.3.2.1.2. Hit Generation/ Validation
          • 3.3.2.1.2.1. mAb Sequencing
          • 3.3.2.1.2.2. Hybridoma Screening
          • 3.3.2.1.2.3. Customized Synthetic Library Screening
          • 3.3.2.1.2.4. Phase Display Screening
          • 3.3.2.1.2.5. High-Throughput Screening
          • 3.3.2.1.2.6. Others
        • 3.3.2.1.3. Lead Identification
          • 3.3.2.1.3.1. Phase Display
          • 3.3.2.1.3.2. ELISA/ADCC & CDC Assay
          • 3.3.2.1.3.3. Array-Based Screening
          • 3.3.2.1.3.4. Hybridoma Screening and Humanization
          • 3.3.2.1.3.5. Bioanalytical Analysis
          • 3.3.2.1.3.6. Others Assays
        • 3.3.2.1.4. Lead Optimization
          • 3.3.2.1.4.1. Humanization
          • 3.3.2.1.4.2. Affinity Analysis
          • 3.3.2.1.4.3. Protein Engineering
          • 3.3.2.1.4.4. In-Vitro/In-Vivo efficacy Assays
          • 3.3.2.1.4.5. Others
    • 3.3.3. Other Biologics

4. Region

  • 4.1. Regional Summary
    • Table: Biologics Drug Discovery Market, By Region, ($ Million), 2022-2033
  • 4.2. Drivers and Restraints
  • 4.3. North America
    • Key Market Participants in North America
    • Business Drivers
    • Business Challenges
    • 4.3.1. Application
      • Table: North America Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.3.2. Product
      • Table: North America Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.3.3. North America (by Country)
      • 4.2.4.1. U.S.
        • Table: U.S. Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.2.4.2. Canada
        • Table: Canada Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.3. Europe
    • 4.3.1. Key Market Participants in Europe
    • 4.3.2. Business Drivers
    • 4.3.3. Business Challenges
    • 4.3.4. Application
      • Table: Europe Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.3.3. Product
      • Table: Europe Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.3.4. Europe (by Country)
      • 4.3.4.1. France
        • Table: France Biologics Drug Discovery Market, By Manufacture Tyoe ($ Million), 2022-2033
      • 4.3.4.2. Germany
        • Table: Germany Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.3. U.K.
        • Table: U.K. Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.4. Switzerland
        • Table: Swizterland Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.5. Rest-of-Europe
        • Table: Rest-of Europe Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.4. Asia-Pacific
    • 4.4.1. Key Market Participants in Asia-Pacific
    • 4.4.2. Business Drivers
    • 4.4.3. Business Challenges
    • 4.4.2. Application
      • Table: Asia-Pacific Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.4.3. Product
      • Table: Asia-Pacific Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.4.4. Asia-Pacific (by Country)
      • 4.4.4.1. China
        • Table: China Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.2. India
        • Table: India Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.3. Japan
        • Table: Japan Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.4. Australia
        • Table: Australia Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.5. Rest-of-Asia-Pacific
        • Table: Rest-of-Asia-Pacific Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.5. Rest-of-the-World
    • 4.5.1. Key Market Participants in Rest-of-the-World
    • 4.5.2. Business Drivers
    • 4.5.3. Business Challenges
    • 4.5.4. Application
      • Table: Rest-of-the-World Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.5.4. Product
      • Table: Rest-of-the-World Biologics Drug Discovery Market, By Type ($ Million), 2022-2033

5. Markets - Competitive Landscape & Company Profiles

  • 5.1. Competitive Landscape
  • 5.2. Company Profile
    • 5.2.1. AbbVie, Inc.
      • 5.2.1.1. Company Overview
      • 5.2.1.2. Product Portfolio
      • 5.2.1.3. Analyst View
    • 5.2.2. Amgen, Inc.
      • 5.2.2.1. Company Overview
      • 5.2.2.2. Product Portfolio
      • 5.2.2.3. Analyst View
    • 5.2.3. Astellas Pharma, Inc.
      • 5.2.3.1. Company Overview
      • 5.2.3.2. Product Portfolio
      • 5.2.3.3. Analyst View
    • 5.2.4. AstraZeneca, Plc
      • 5.2.4.1. Company Overview
      • 5.2.4.2. Product Portfolio
      • 5.2.4.3. Analyst View
    • 5.2.5. Bayer AG
      • 5.2.5.1. Company Overview
      • 5.2.5.2. Product Portfolio
      • 5.2.5.3. Analyst View
    • 5.2.6. Bicon Ltd.
      • 5.2.6.1. Company Overview
      • 5.2.6.2. Product Portfolio
      • 5.2.6.3. Analyst View
    • 5.2.7. Boehringer Ingelheim GmbH
      • 5.2.7.1. Company Overview
      • 5.2.7.2. Product Portfolio
      • 5.2.7.3. Analyst View
    • 5.2.8. Bristol-Myers Squibb Company
      • 5.2.8.1. Company Overview
      • 5.2.8.2. Product Portfolio
      • 5.2.8.3. Analyst View
    • 5.2.9. Eli Lily and Company
      • 5.2.9.1. Company Overview
      • 5.2.9.2. Product Portfolio
      • 5.2.9.3. Analyst View
    • 5.2.10. F.Hoffmann-La Roche AG
      • 5.2.10.1. Company Overview
      • 5.2.10.2. Product Portfolio
      • 5.2.10.3. Analyst View
    • 5.2.11. GenScript
      • 5.2.11.1. Company Overview
      • 5.2.11.2. Product Portfolio
      • 5.2.11.3. Analyst View
    • 5.2.12. Gilead Sciences, Inc.
      • 5.2.12.1. Company Overview
      • 5.2.12.2. Product Portfolio
      • 5.2.12.3. Analyst View
    • 5.2.13. GlaxoSmithKline, Plc
      • 5.2.13.1. Company Overview
      • 5.2.13.2. Product Potfolio
      • 5.2.13.3. Analyst View
    • 5.2.14. Johnson and Johnson
      • 5.2.14.1. Company Overview
      • 5.2.14.2. Product Potfolio
      • 5.2.14.4. Analyst View
    • 5.2.15. Laboratory Corporation of America Holdings
      • 5.2.15.1. Company Overview
      • 5.2.15.2. Product Potfolio
      • 5.2.15.3. Analyst View
    • 5.2.16. Merck KGaA
      • 5.2.16.1. Company Overview
      • 5.2.16.2. Product Potfolio
      • 5.2.16.4. Analyst View
    • 5.2.17. Novartis AG
      • 5.2.17.1. Company Overview
      • 5.2.17.2. Product Potfolio
      • 5.2.17.3. Analyst View
    • 5.2.18. Novo Nordisk
      • 5.2.18.1. Company Overview
      • 5.2.18.2. Product Potfolio
      • 5.2.18.3. Analyst View
    • 5.2.19. Pfizer
      • 5.2.19.1. Company Overview
      • 5.2.19.2. Product Potfolio
      • 5.2.19.3. Analyst View
    • 5.2.20. Sanofi
      • 5.2.20.1. Company Overview
      • 5.2.20.2. Product Potfolio
      • 5.2.20.3. Analyst View
    • 5.2.21. Teva Pharmaceutical Industries, Ltd.
      • 5.2.21.1. Company Overview
      • 5.2.21.2. Product Potfolio
      • 5.2.21.3. Analyst View